2 results
Not approvedWill not start
Primary:* To prove the superiority of a 48-weeks treatment with 3.2 g/day delayedreleasephosphatidylcholine (LT-02) versus placebo for the maintenance ofremission in patients with ulcerative colitis (UC)Secondary:* To study safety and tolerability…
Divergent Low Level Laser Therapy as novel treatment for oral mucositis in pediatric cancer patients
Primary Objective: - To assess the effect of divergent LLLT on the number of days of mucositis > grade 1Secondary Objective(s): - To assess the effect of divergent LLLT on the severity of mucositis - To assess the effect of divergent LLLT on…